Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD subjects. As secondary measures, we will also provide the essential human data to guide the design of future studies to test the efficacy of GSPE in mitigating cognitive deterioration in AD patients.

Key facts

Study ID

NCT02033941

Run by

Hillel Grossman

People needed

10

Starts

2018-07-03

Expected to finish

2019-10-04

Last updated by the study team

2024-10-15

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• NINCDS/ADRDA criteria for probable AD
• MMSE between 12-26
• Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks
• Home monitoring available for supervision of medications
• Caregiver available to accompany patient to all visits and willing to participate in study as informant
• Fluent in English or Spanish
• Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests
• Stable doses of non-excluded medication
• No evidence of hepatic insufficiency
• Able to swallow oral medications
• Ability to participate in the informed consent process

You may not qualify if…

• History of hypotension or unstable hypertension
• Active hepatic or renal disease
• Use of another investigational drug within the past two months
• History of clinically significant stroke
• History of seizure or head trauma with disturbance of consciousness within the past two years
• Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode that is not in remission for less than 12 months
• Women of child-bearing age unless using effective birth control or at least one year post-menopausal or surgically menopausal
• Any ferrous or metallic materials which are contraindicated for MRI
• Medication Exclusions
• Current use of drugs with significant anticholinergic or antihistaminic properties

Where it is running

• Mount Sinai Alzheimer's Disease Research Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.